Proteomics in clinical trials and practice: Present uses and future promise

Molecular and Cellular Proteomics

Volumn 5, Issue 10, 2006, Pages 1819-1829

  Azad, Nilofer S ^a   Rasool, Nabila ^a   Annunziata, Christina M ^a   Minasian, Lori ^a   Whiteley, Gordon ^a   Kohn, Elise C ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTINEOPLASTIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN A4; BEVACIZUMAB; BRCA1 PROTEIN; CA 125 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CATHEPSIN D; GEFITINIB; HEAT SHOCK PROTEIN 70; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN; PREALBUMIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN TYROSINE KINASE INHIBITOR; PROTEOME; PYRIDO[2,3 D]PYRIMIDINE DERIVATIVE; SORAFENIB; SYNAPTOPHYSIN ALPHA ACTIVATOR; TUMOR MARKER; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; BLADDER CARCINOMA; BLOOD ANALYSIS; BREAST CANCER; CANCER; CANCER RESEARCH; CEREBROSPINAL FLUID ANALYSIS; CHRONIC MYELOID LEUKEMIA; CLINICAL PRACTICE; CLINICAL TRIAL; DOSE RESPONSE; DRUG MECHANISM; DRUG MONITORING; DRUG POTENTIATION; DRUG RESPONSE; DRUG TARGETING; EARLY DIAGNOSIS; FUNCTIONAL PROTEOMICS; GASTROINTESTINAL STROMAL TUMOR; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; LASER MICRODISSECTION; MASS SPECTROMETRY; MOLECULAR GENETICS; NONHUMAN; OVARY CANCER; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MICROARRAY; PROTEIN MODIFICATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; PROTEOMICS; QUALITY CONTROL; REVIEW; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; TISSUE MICROARRAY; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; URINALYSIS; VALIDATION PROCESS;

CLINICAL TRIALS; HUMANS; MICRODISSECTION; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TISSUE ARRAY ANALYSIS;

EID: 33750612372     PISSN: 15359476     EISSN: None     Source Type: Journal    
DOI: 10.1074/mcp.R600008-MCP200     Document Type: Review

References (65)

1. Engwegen, J. Y., Gast, M. C., Schellens, J. H., and Beijnen, J. H. (2006) Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry. Trends Pharmacol. Sci. 27, 251-259
2. Petricoin, E. F., Ornstein, D. K., and Liotta, L. A. (2004) Clinical proteomics: Applications for prostate cancer biomarker discovery and detection. Urol. Oncol. 22, 322-328
3. Banks, R. E., Dunn, M. J., Hochstrasser, D. F., Sanchez, J. C., Blackstock, W., Pappin, D. J., and Selby, P. J. (2000) Proteomics: new perspectives, new biomedical opportunities. Lancet 356, 1749-1756
4. Stein, L. D. (2004) Human genome: end of the beginning. Nature 431, 915-916
5. Schnitt, S. J. (2001) Traditional and newer pathologic factors. J. Natl. Cancer Inst. Monogr. 30, 22-26
6. Donegan, W. L. (1997) Tumor-related prognostic factors for breast cancer. CA Cancer J. Clin. 47, 28-51
7. Alalya, A., Al-Mohanna, M., and Linder, S. (2005) Clinical cancer proteomics: promises and pitfalls. J. Proteome Res. 4, 1213-1222
8. Ariazi, E. A., Ariazi, J. L., Cordera, F., and Jordan, V. C. (2006) Estrogen receptors as therapeutic targets in breast cancer. Curr. Top. Med. Chem. 6, 195-216
9. Cai, Z., Chiu, J. F., and He, Q. Y. (2004) Application of proteomics in the study of tumor metastasis. Genomics Proteomics Bioinformatics 2, 152-166
10. Hoehn, G. T., and Suffredini, A. F. (2005) Proteomics. Crit. Care Med. 33, (suppl.) S444-S448
11. Clarke, C. H., Buckley, J. A., and Fung, E. T. (2005) SELDI-TOF-MS proteomics of breast cancer. Clin. Chem. Lab. Med. 43, 1314-1320
12. Domon, B., and Aebersold, R. (2006) Mass spectrometry and protein analysis. Science 312, 212-217
13. Pusch, W., Flocco, M. T., Leung, S. M., Thiele, H., and Kostrzewa, M. (2003) Mass spectrometry-based clinical proteomics. Pharmacogenomics 4, 463-476
14. Petricoin, E. F., Ardekani, A. M., Hitt, B. A., Levine, P. J., Fusaro, V. A., Steinberg, S. M., Mills, G. B., Simone, C., Fishman, D. A., Kohn, E. C., and Liotta, L. A. (2002) Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359, 572-577
15. Rapkiewicz, A. V., Espina, V., Petricoin, E. F., 3rd, and Liotta, L. A. (2004) Biomarkers of ovarian tumours. Eur. J. Cancer 40, 2604-2612
16. Ye, B., Cramer, D. W., Skates, S. J., Gygi, S. P., Pratomo, V., Fu, L., Horick, N. K., Licklider, L. J., Schorge, J. O., Berkowitz, R. S., and Mok, S. C. (2003) Haptoglobin-α subunit as potential serum biomarker in ovarian cancer: Identification and characterization using proteomic profiling and mass spectrometry. Clin. Cancer Res. 9, 2904-2911
17. Papsidero, L. D., Kuriyama, M., Wang, M. C., Horoszewicz, J., Leong, S. S., Valenzuela, L., Murphy, G. P., and Chu, T. M. (1981) Prostate antigen: a marker for human prostate epithelial cells. J. Natl. Cancer Inst. 66, 37-42
18. Adam, B. L., Qu, Y., Davis, J. W., Ward, M. D., Clements, M. A., Cazares, L. H., Semmes, O. J., Schellhammer, P. F., Yasui, Y., Feng, Z., and Wright, G. L., Jr. (2002) Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res. 62, 3609-3614
19. Petricoin, E. F., III, Ornstein, D. K., Paweletz, C. P., Ardekani, A., Hackett, P. S., Hitt, B. A., Velassco, A., Trucco, C., Wiegand, L., Wood, K., Simone, C. B., Levine, P. J., Linehan, W. M., Emmert-Buck, M. R., Steinberg, S. M., Kohn, E. C., and Liotta, L. A. (2002) Serum proteomic patterns for detection of prostate cancer. J. Natl. Cancer Inst. 94, 1576-1578
20. Lehrer, S., Roboz, J., Ding, H., Zhao, S., Diamond, E. J., Holland, J. F., Stone, N. N., Droller, M. J., and Stock, R. G. (2003) Putative protein markers in the sera of men with prostatic neoplasms. BJU Int. 92, 223-225
21. Wang, X., Yu, J., Sreekumar, A., Varambally, S., Shen, R., Giacherio, D., Mehra, R., Montie, J. E., Pienta, K. J., Sanda, M. G., Kantoff, P. W., Rubin, M. A., Wei, J. T., Ghosh, D., and Chinnaiyan, A. M. (2005) Autoantibody signatures in prostate cancer. N. Engl. J. Med. 353, 1224-1235
22. Li, J., Zhang, Z., Rosenzweig, J., Wang, Y. Y., and Chan, D. W. (2002) Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin. Chem. 48, 1296-1304
23. Hu, Y., Zhang, S. Z., Yu, J. K., Liu, J., Zheng, S., and Hu, X. (2005) Diagnostic application of serum protein pattern and artificial neural network software in breast cancer. Ai Zheng 24, 67-71
24. Diamandis, E. P. (2004) Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J. Natl. Cancer Inst 96, 353-356
25. Laronga, C., Becker, S., Watson, P., Gregory, B., Cazares, L., Lynch, H., Perry, R. R., Wright, G. L., Jr., Drake, R. R., and Semmes, O. J. (2003) SELDI-TOF serum profiling for prognostic and diagnostic classification of breast cancers. Dis. Markers 19, 229-238
26. Becker, S., Cazares, L. H., Watson, P., Lynch, H., Semmes, O. J., Drake, R. R., and Laronga, C. (2004) Surfaced-enhanced laser desorption/ ionization time-of-flight (SELDI-TOF) differentiation of serum protein profiles of BRCA-1 and sporadic breast cancer. Ann. Surg. Oncol. 11, 907-914
27. Pieper, R., Gatlin, C. L., McGrath, A. M., Makusky, A. J., Mondal, M., Seonarain, M., Field, E., Schatz, C. R., Estock, M. A., Ahmed, N., Anderson, N. G., and Steiner, S. (2004) Characterization of the human urinary proteome: a method for high-resolution display of urinary proteins on two-dimensional electrophoresis gels with a yield of nearly 1400 distinct protein spots. Proteomics 4, 1159-1174
28. Vlahou, A., Schellhammer, P. F., Mendrinos, S., Patel, K., Kondylis, F. I., Gong, L., Nasim, S., and Wright, G. L., Jr. (2001) Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am. J. Pathol. 158, 1491-1502
29. Kageyama, S., Isono, T., Iwaki, H., Wakabayashi, Y., Okada, Y., Kontani, K., Yoshimura, K., Terai, A., Arai, Y., and Yoshiki, T. (2004) Identification by proteomic analysis of calreticulin as a marker for bladder cancer and evaluation of the diagnostic accuracy of its detection in urine. Clin. Chem. 50, 857-866
30. Celis, J. E., Gromova, I., Moreira, J. M., Cabezon, T., and Gromov, P. (2004) Impact of proteomics on bladder cancer research. Pharmacogenomics 5, 381-394
31. Veenstra, T. D., Conrads, T. P., Hood, B. L., Avellino, A. M., Ellenbogen, R. G., and Morrison, R. S. (2005) Biomarkers: mining the biofluid proteome. Mol. Cell. Proteomics 4, 409-418
32. Jiang, L., Lindpaintner, K., Li, H. F., Gu, N. F., Langen, H., He, L., and Fountoulakis, M. (2003) Proteomic analysis of the cerebrospinal fluid of patients with schizophrenia. Amino Acids 25, 49-57
33. Castaño, E. M., Roher, A. E., Esh, C. L., Kokjohn, T. A., and Beach, T. (2006) Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects. Neurol. Res. 28, 155-163
34. Zheng, P. P., Luider, T. M., Pieters, R., Avezaat, C. J., van den Bent, M. J., Sillevis Smitt, P. A., and Kros, J. M. (2003) Identification of tumor-related proteins by proteomic analysis of cerebrospinal fluid from patients with primary brain tumors. J. Neuropathol. Exp. Neurol. 62, 855-862
35. Sauter, E. R., Shan, S., Hewett, J. E., Speckman, P., and Du Bois, G. C. (2005) Proteomic analysis of nipple aspirate fluid using SELDI-TOF-MS. Int. J. Cancer 114, 791-796
36. Pawlik, T. M., Fritsche, H., Coombes, K. R., Xiao, L., Krishnamurthy, S., Hunt, K. K., Pusztai, L., Chen, J. N., Clarke, C. H., Arun, B., Hung, M. C., and Kuerer, H. M. (2005) Significant differences in nipple aspirate fluid protein expression between healthy women and those with breast cancer demonstrated by time-of-flight mass spectrometry. Breast Cancer Res. Treat. 89, 149-157
37. Alexander, H., Stegner, A. L., Wagner-Mann, C., Du Bois, G. C., Alexander, S., and Sauter, E. R. (2004) Proteomic analysis to identify breast cancer biomarkers in nipple aspirate fluid. Clin. Cancer Res. 10, 7500-7510
38. Paweletz, C. P., Trock, B., Pennanen, M., Tsangaris, T., Magnant, C., Liotta, L. A., and Petricoin, E. F., III (2001) Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: potential for new biomarkers to aid in the diagnosis of breast cancer. Dis. Markers 17, 301-307
39. Varambally, S., Yu, J., Laxman, B., Rhodes, D. R., Mehra, R., Tomlins, S. A., Shah, R. B., Chandran, U., Monzon, F. A., Becich, M. J., Wei, J. T., Pienta, K. J., Ghosh, D., Rubin, M. A., and Chinnaiyan, A. M. (2005) Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 8, 393-406
40. Yanagisawa, K., Shyr, Y., Xu, B. J., Massion, P. P., Larsen, P. H., White, B. C., Roberts, J. R., Edgerton, M., Gonzalez, A., Nadaf, S., Moore, J. H., Caprioli, R. M., and Carbons, D. P. (2003) Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet 362, 433-439
41. Chen, G., Gharib, T. G., Wang, H., and Huang, C. C., Kuick, R., Thomas, D. G., Shedden, K. A., Misek, D. E., Taylor, J. M., Giordano, T. J., Kardia, S. L., Iannettoni, M. D., Yee, J., Hogg, P. J., Orringer, M. B., Hanash, S. M., and Beer, D. G. (2003) Protein profiles associated with survival in lung adenocarcinoma. Proc. Natl. Acad. Sci. U. S. A. 100, 13537-13542
42. Luo, F., Liu, X., Yan, N., Li, S., Cao, G., Cheng, Q., Xia, Q., and Wang, H. (2006) Hypoxia-inducible transcription factor-1alpha promotes hypoxia-induced A549 apoptosis via a mechanism that involves the glycolysis pathway. BMC Cancer 6, 26
43. Zhang, D., Tal, L. K., Wong, L. L., Chiu, L. L., Sethi, S. K., and Koay, E. S. (2005) Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer. Mol. Cell. Proteomics 4, 1686-1696
44. Shichijo, S., Azuma, K., Komatsu, N., Ito, M., Maeda, Y., Ishihara, Y., and Itoh, K. (2004) Two proliferation-related proteins, TYMS and PGK1, could be new cytotoxic T lymphocyte-directed tumor-associated antigens of HLA-A2+ colon cancer. Clin. Cancer Res. 10, 5828-5836
45. Xing, X., Lai, M., Gartner, W., Xu, E., Huang, Q., Li, H., and Chen, G. (2006) Identification of differentially expressed proteins in colorectal cancer by proteomics: down-regulation of secretagogin. Proteomics 6, 2916-2923
46. Cheung, P. K., Woolcock, B., Adomat, H., Sutcliffe, M., Bainbridge, T. C., Jones, E. C., Webber, D., Kinahan, T., Sadar, M., Gleave, M. E., and Vielkind, J. (2004) Protein profiling of microdissected prostate tissue links growth differentiation factor 15 to prostate carcinogenesis. Cancer Res. 64, 5929-5933
47. Orth, A. P., Batalov, S., Perrone, M., and Chanda, S. K. (2004) The promise of genomics to identify novel therapeutic targets. Expert Opin. Ther. Targets 8, 587-596
48. Godl, K., Wissing, J., Kurtenbach, A., Habenberger, P., Blencke, S., Gutbrod, H., Salassidis, K., Stein-Gerlach, M., Missio, A., Cotten, M., and Daub, H. (2003) An efficient proteomics method to identify the cellular targets of protein kinase inhibitors. Proc. Natl. Acad. Sci. U. S. A. 100, 15434-15439
49. Brehmer, D., Godl, K., Zech, B., Wissing, J., and Daub, H. (2004) Proteome-wide identification of cellular targets affected by bisindolylmaleimide-type protein kinase C inhibitors. Mol. Cell. Proteomics 3, 490-500
50. Wissing, J., Godl, K., Brehmer, D., Blencke, S., Weber, M., Habenberger, P., Stein-Gerlach, M., Missio, A., Cotten, M., Muller, S., and Daub, H. (2004) Chemical proteomic analysis reveals alternative modes of action for pyrido[2,3-d]pyrimidine kinase inhibitors. Mol. Cell. Proteomics 3, 1181-1193
51. Parmar, S., Katsoulidis, E., Verma, A., Li, Y., Sassano, A., Lal, L., Majchrzak, B., Ravandi, F., Tallman, M. S., Fish, E. N., and Platanias, L. C. (2004) Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells. J. Biol. Chem. 279, 25345-25352
52. Kolch, W., Mischak, H., and Pitt, A. R. (2005) The molecular make-up of a tumour: proteomics in cancer research. Clin. Sci. (Lond.) 108, 369-383
53. Huang, J., Zhu, H., Haggerty, S. J., Spring, D. R., Hwang, H., Jin, F., Snyder, M., and Schreiber, S. L. (2004) Finding new components of the target of rapamycin (TOR) signaling network through chemical genetics and proteome chips. Proc. Natl. Acad. Sci. U. S. A. 101, 16594-16599
54. Hu, W., Wu, W., Yeung, S. C., Freedman, R. S., Kavanagh, J. J., and Verschraegen, C. F. (2002) Increased expression of heat shock protein 70 in adherent ovarian cancer and mesothelioma following treatment with manumycin, a farnesyl transferase inhibitor. Anticancer Res. 22, 665-672
55. Sjoholt, G., Anensen, N., Wergeland, L., Mc Cormack, E., Bruserud, O., and Gjertsen, B. T. (2005) Proteomics in acute myelogenous leukaemia (AML): methodological strategies and identification of protein targets for novel antileukaemic therapy. Curr. Drug Targets 6, 631-646
56. Alessandro, R., Belluco, C., and Kohn, E. C. (2005) Proteomic approaches in colon cancer: promising tools for new cancer markers and drug target discovery. Clin. Colorectal Cancer 4, 396-402
57. Celis, J. E., Gromov, P., Cabezon, T., Moreira, J. M., Ambartsumian, N., Sandelin, K., Rank, F., and Gromova, I. (2004) Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment: a novel resource for biomarker and therapeutic target discovery. Mol. Cell. Proteomics 3, 327-344
58. Chignard, N., and Beretta, L. (2004) Proteomics for hepatocellular carcinoma marker discovery. Gastroenterology 127, Suppl. 1, S120-S125
59. Posadas, E. M., Hussain, M. M., Espina, V., Kotz, H. L., Minasian, L. M., Shreeve, S. M., Premkumar, A., Liotta, L. A., Steinberg, S. M., and Kohn, E. C. (2004) A phase II clinical trial with proteomic profiling of imatinib mesylate in patients with refractory or relapsed epithelial ovarian cancer (EOC), in Proceedings of the American Society of Clinical Oncology 40th Annual Meeting, New Orleans, Louisiana, June 5-8, 2004, Abstr. 9651, American Society of Clinical Oncology, Alexandria, VA
60. Hobbs, S. K., Shi., G., Homer, R., Harsh, G., Atlas, S., and Bednarski, M. (2003) Magnetic resonance image guided proteomics of human glioblastoma multiforme. J. Magn. Reson. Imaging 18, 530-536
61. Liotta, L. A., Kohn, E. C., and Petricoin, E. F. (2001) Clinical proteomics: personalized molecular medicine. J. Am. Med. Assoc. 286, 2211-2214
62. Kaklamani, V. G., and Gradishar, W. J. (2006) Gene expression in breast cancer. Curr. Treat Options Oncol. 7, 123-128
63. Cobleigh, M. A., Tabesh, B., Bitterman, P., Baker, J., Cronin, M., Liu, M. L., Borchik, R., Mosquera, J. M., Walker, M. G., and Shak, S. (2005) Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. Clin. Cancer Res. 11, 8623-8631
64. Irish, J. M., Hovland, R., Krutzik, P. O., Perez, O. D., Bruserud, O., Gjertsen, B. T., and Nolan, G. P. (2004) Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell 118, 217-228
65. Azad, N. S., Posades, E. M., Kwitkowski, V. E., Annunziata, C. M., Barrett, T., Premkumar, A., Kotz, H. L., Sarosy, G. A., Minasian, L. M., and Kohn, E. C. (2006) Increased efficacy and toxicity with combination anti-VEGF therapy using sorafenib and bevacizumab, in Proceedings of the American Society of Clinical Oncology 42nd Annual Meeting, Atlanta, GA, June 2-6, 2006, Abstr. 3004, American Society of Clinical Oncology, Alexandria, VA